As Asset Lead, accountable for the largest portfolio in a key PRA partnership, providing strategic and operational oversight to global, multi- functional teams who exceeded or met milestones for 7 studies across 120 countries and 3 indications. As as result, two new indications were approved for this molecular entity.Therapeutic Areas: Immunology, Gastroenterology, Oncology

Led Sarah Cannon’s strategic Clinical Development Department within their CRO, Development Innovations. Supported interdisciplinary teams and Sarah Cannon physicians in successful phase I-III oncology program/portfolio delivery leading to new drug approvals and strengthened client partnerships. Spearheaded strategic initiatives such as executive dashboard reporting and study/program "visioning" to better plan and deliver drug development support for our clients. Therapeutic Areas: Oncology, Immunology

Lead multi-specialty physician group teams in exceptional phase I-IV study performance from subject recruitment to database lock.Responsible for the expansion of the Translational Research Division to better assist Sponsors in quickly developing targeted therapies via providing high-quality specimens and key subject data.

Led Celerion’s Phase IIa study initiative by developing infrastructure, processes and SOPs for successful Phase IIa study executionIdentified, recruited and built positive strategic partnerships with world leading renal insufficiency and hepatic impairment investigator expertsBuilt and mentored high-performing cross-functional study teams and oversaw successful clinical operations on multiple studiesDeveloped Key Account Management Plans and spearheaded governance committees to strengthen relationships with MDS Strategic AccountsSpearheaded MDS GCD profitability initiative in which financial and operational challenges were identified and resolved or improved in collaboration of project teams; resulting in $17M quarter revenue increase and improvement of all client satisfaction scoresTherapeutic Areas: Oncology, Special Populations (Renal insufficiency and Hepatic Impairment), Immunology

Executive Director, Service Delivery, Covance: 2004-2006Senior Leader responsible for ensuring operational excellence for a portfolio of 15 clients and 31 studies with an annual contract value of $95M; granted repeat business from 10/15 clients Oversaw large global teams to ensure outstanding service delivery via effective resource management, optimization of financial and operational performance as well as risk management mitigationTherapeutic areas across 31 studies: Oncology, Anti-infective, ImmunologyProject Director, Clinical Operations, Covance: 1998-2004 Effectively led global Phase II-III program activities between the clinical, data, safety, financial, medical writing, biometrics and regulatory departments (nine studies and five clients)Indications: Psoriasis, Community Acquired Pneumonia (CAP) and Hospital Acquired Pneumonia (HAP)Project Manager, Clinical Operations, Covance: 1996-1998Successfully accelerated a large, 3.5 year, global Phase II-III immunomodulator program involving seven (7) studies, 11 countries and 2,200 subjects, resulting in a six month decrease in the client’s drug development timelineIndications: COPD, Migraine, Hepatitis C, Psoriasis

Senior Clinical Research Associate, Norvir® /Antiviral Clinical Research: 1995-1996Clinical Research Associate, Hytrin® /Cardiovascular Clinical Research: 1992-1995 Toxicology Technician, Experimental Toxicology: 1991-1992